Browse News
Filter News
Found 20 articles
-
The Inflation Reduction Act, “march-in rights” to take back patents and M&A were among the issues discussed at a Sunday panel in San Francisco ahead of Monday’s start of the J.P. Morgan conference.
-
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
11/28/2023
Korro Bio, Inc. today announced the appointment of Rachel Meyers, PhD, to the Company’s Board of Directors.
-
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder
11/13/2023
Tonix Pharmaceuticals Holding Corp. announced that the first participant was enrolled in an investigator-initiated Phase 2 study of TNX-1900 for improving bone health in children with autism spectrum disorder, named the BOX study, at Massachusetts General Hospital.
-
Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer
9/11/2023
Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, today announced the appointment of Philip J. Vickers, Ph.D., as President and Chief Executive Officer.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
Third Rock-founded Faze Medicines appears to be shuttering operations, with several former employees signaling they are looking for new jobs.
-
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
-
Faze Medicines Appoints New Senior Vice President, Head of People & Culture
8/5/2021
Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, announced that Daryn Lewis has joined the company as Senior Vice President, Head of People & Culture.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Faze Medicines Appoints Douglas Kerr, M.D., Ph.D., to its Board of Directors
5/4/2021
Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Douglas Kerr, M.D., Ph.D., to its board of directors.
-
BioSpace Movers & Shakers, Jan. 29
1/29/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
1/25/2021
Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO).
-
Biopharma Money on the Move: December 9-15
12/16/2020
A roundup of life sciences companies raking in the cash. -
Cambridge-based Faze Medicines, the biotechnology company that develops therapeutics based on biomolecular condensates, announced today that it has raised $81 million in a Series A round of financing.
-
Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease
12/10/2020
Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced its launch and Series A financing of $81 million.
-
The company is presenting the study of Tagrisso during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Sunday, May 31.
-
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data
11/19/2019
Amidst rumors that Novartis might be interested in an acquisition, The Medicines Company announced data from ORION-10, the second of three 19-month Phase III trials of inclisiran for lowering cholesterol. -
Biopharma has several unique challenges, but one of them is the patent cliff. In an industry where only about one in 10 compounds actually makes it to market on average, those drugs aren’t able to stay on the market very long before their patents end and generic competition begins.
-
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
-
BioPharm Executive: 5 Reasons To Hate Biotech
10/29/2014